87,345 AbbVie Inc. $ABBV Shares Purchased by Bank Julius Baer & Co. Ltd Zurich

Key Points

• Bank Julius Baer increased its AbbVie stake by 19.2% in the third quarter, purchasing 87,345 shares and bringing its holdings to 543,272 shares valued at approximately $142.2 million. Institutional investors collectively own 70.23% of ABBV.
• AbbVie exceeded third-quarter expectations, reporting adjusted EPS of $3.82 versus the $3.73 consensus and revenue of $17.40 billion, up 10.3% year over year. Management raised its 2026 adjusted EPS outlook and announced a 5.2% dividend increase.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $279.86, though investors remain focused on valuation and concentration risks as Humira and aesthetics revenue declined despite strong Skyrizi, Rinvoq and neuroscience growth.

Bank Julius Baer & Co. Ltd Zurich grew its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 19.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 543,272 shares of the company's stock after acquiring an additional 87,345 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich's holdings in AbbVie were worth $142,237,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of ABBV. Pinkerton Wealth LLC raised its position in AbbVie by 3.0% in the 3rd quarter. Pinkerton Wealth LLC now owns 29,837 shares of the company's stock valued at $7,805,000 after purchasing an additional 863 shares during the last quarter. Virtue Capital Management LLC grew its position in shares of AbbVie by 9.9% during the third quarter. Virtue Capital Management LLC now owns 4,719 shares of the company's stock worth $1,234,000 after purchasing an additional 424 shares in the last quarter. Nippon Life Global Investors Americas Inc. increased its stake in AbbVie by 42.5% during the 3rd quarter. Nippon Life Global Investors Americas Inc. now owns 59,950 shares of the company's stock worth $15,682,000 after buying an additional 17,870 shares in the last quarter. DecisionMap Wealth Management LLC raised its stake in shares of AbbVie by 3.2% during the third quarter. DecisionMap Wealth Management LLC now owns 1,207 shares of the company's stock worth $316,000 after purchasing an additional 37 shares during the last quarter. Finally, Bell Investment Advisors Inc boosted its holdings in shares of AbbVie by 1.3% in the 3rd quarter. Bell Investment Advisors Inc now owns 3,809 shares of the company's stock valued at $996,000 after purchasing an additional 48 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ABBV. Citigroup lifted their target price on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Wednesday, July 15th. UBS Group lifted their target price on AbbVie from $260.00 to $275.00 and gave the stock a "neutral" rating in a research report on Tuesday, October 6th. Morgan Stanley boosted their price objective on AbbVie from $296.00 to $310.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. JPMorgan Chase & Co. upped their price objective on shares of AbbVie from $285.00 to $300.00 and gave the company an "overweight" rating in a research note on Thursday, October 8th. Finally, Scotiabank lifted their target price on AbbVie from $280.00 to $320.00 and gave the stock an "outperform" rating in a report on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and an average target price of $279.86.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Price Performance

AbbVie stock opened at $294.80 on Monday. The stock has a market capitalization of $520.85 billion, a PE ratio of 50.74, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $298.74. The business has a 50 day simple moving average of $269.35 and a 200-day simple moving average of $237.23.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts' consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. The company's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.86 earnings per share. On average, equities research analysts anticipate that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a $1.82 dividend. This is an increase from AbbVie's previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. AbbVie's dividend payout ratio (DPR) is 119.10%.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.